U.S. Markets closed

Retrophin neurological disorder drug misses late-stage study main goal

Aug 22 (Reuters) - Retrophin Inc said on Thursday its treatment for a rare neurological disorder failed to meet the main goal in a late-stage study.

The treatment, fosmetpantotenate, was being tested in 84 patients with pantothenate kinase-associated neurodegeneration, a rare, genetic and life-threatening disorder.

The treatment, tested against placebo, also failed to meet its secondary goal, the company said. (Reporting by Aakash Jagadeesh Babu in Bengaluru; Editing by Shinjini Ganguli)